Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of new therapeutics.
- The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of new therapeutics.
- Pluristyx offers a unique product and technology platform in the stem cell biology field for development of new therapies while reducing timelines and downstream costs.
- Through the agreement, Charles River will distribute Pluristyx’s wild-type and genetically engineered iPSCs as well as their comprehensive portfolio of normal and disease state ES cell lines.
- The addition of Pluristyx’s offerings complements Charles River’s expansive portfolio of high-quality human cellular materials.